Low-dose doxycycline induces Chlamydia trachomatis persistence in HeLa cells. 2020

Antonella Marangoni, and Chiara Zalambani, and Giacomo Marziali, and Melissa Salvo, and Romana Fato, and Claudio Foschi, and Maria Carla Re
University of Bologna, Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Microbiology Unit, Via Massarenti 9, Bologna, Italy.

Chlamydia persistence is a viable but non-replicative stage, induced by several sub-lethal stressor agents, including beta-lactam antibiotics. So far, no data about the connection between doxycycline and chlamydial persistence has been described in literature. We investigated the ability of doxycycline to induce C. trachomatis (CT) persistence in an in vitro model of epithelial cell infection (HeLa cells), comparing the results with the well-established model of penicillin-induced persistence. The effect of doxycycline was explored on 10 different CT strains by analysing (i) the presence of aberrant inclusions, (ii) chlamydial recovery, (iii) the expression of different chlamydial genes (omcB, euo, Ct110, Ct604, Ct755, HtrA) and (iv) the effects on epithelial cell viability. For each strain, the presence of foreign genomic islands responsible of tetracycline resistance was excluded. We found that low doses of doxycycline can induce a condition of CT persistence. For concentrations of doxycycline equal to 0.03-0.015 mg/L, CT inclusions are smaller and aberrant and CT cycle is characterized by the presence of viable but non-dividing RBs with the complete abolishment of chlamydial cytotoxic effect. Infectious EBs can be recovered after removal of the drug. During doxycycline-induced persistence, the expression of the late gene omcB is decreased, indicating the blocking of RB-to-EB conversion. Conversely, as for penicillin G, a significant up-regulation of the stress response HtrA gene is found in doxycycline-treated cells. This study provides a novel in vitro cell model to examine the characteristics of doxycycline-induced persistent CT infection.

UI MeSH Term Description Entries
D010406 Penicillins A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065) Antibiotics, Penicillin,Penicillin,Penicillin Antibiotics
D002690 Chlamydia Infections Infections with bacteria of the genus CHLAMYDIA. Infections, Chlamydia,Chlamydia Infection,Infection, Chlamydia
D002692 Chlamydia trachomatis Type species of CHLAMYDIA causing a variety of ocular and urogenital diseases.
D004318 Doxycycline A synthetic tetracycline derivative with similar antimicrobial activity. 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S-(4alpha,4aalpha,5alpha,5aalpha,6alpha,12aalpha))-,Alpha-6-Deoxyoxytetracycline,Atridox,BMY-28689,BU-3839T,Doryx,Doxycycline Calcium,Doxycycline Calcium Salt (1:2),Doxycycline Hemiethanolate,Doxycycline Hyclate,Doxycycline Monohydrate,Doxycycline Monohydrochloride, 6-epimer,Doxycycline Monohydrochloride, Dihydrate,Doxycycline Phosphate (1:1),Doxycycline-Chinoin,Hydramycin,Oracea,Periostat,Vibra-Tabs,Vibramycin,Vibramycin Novum,Vibravenos,Alpha 6 Deoxyoxytetracycline,BMY 28689,BMY28689,BU 3839T,BU3839T,Doxycycline Chinoin,Doxycycline Monohydrochloride, 6 epimer,Vibra Tabs
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Antonella Marangoni, and Chiara Zalambani, and Giacomo Marziali, and Melissa Salvo, and Romana Fato, and Claudio Foschi, and Maria Carla Re
February 2021, World journal of microbiology & biotechnology,
Antonella Marangoni, and Chiara Zalambani, and Giacomo Marziali, and Melissa Salvo, and Romana Fato, and Claudio Foschi, and Maria Carla Re
November 1994, Infection and immunity,
Antonella Marangoni, and Chiara Zalambani, and Giacomo Marziali, and Melissa Salvo, and Romana Fato, and Claudio Foschi, and Maria Carla Re
April 1976, Infection and immunity,
Antonella Marangoni, and Chiara Zalambani, and Giacomo Marziali, and Melissa Salvo, and Romana Fato, and Claudio Foschi, and Maria Carla Re
July 2002, Infection and immunity,
Antonella Marangoni, and Chiara Zalambani, and Giacomo Marziali, and Melissa Salvo, and Romana Fato, and Claudio Foschi, and Maria Carla Re
January 2006, Microbiological research,
Antonella Marangoni, and Chiara Zalambani, and Giacomo Marziali, and Melissa Salvo, and Romana Fato, and Claudio Foschi, and Maria Carla Re
October 1987, European journal of clinical microbiology,
Antonella Marangoni, and Chiara Zalambani, and Giacomo Marziali, and Melissa Salvo, and Romana Fato, and Claudio Foschi, and Maria Carla Re
December 2020, Journal of medical microbiology,
Antonella Marangoni, and Chiara Zalambani, and Giacomo Marziali, and Melissa Salvo, and Romana Fato, and Claudio Foschi, and Maria Carla Re
June 2010, The Journal of infectious diseases,
Antonella Marangoni, and Chiara Zalambani, and Giacomo Marziali, and Melissa Salvo, and Romana Fato, and Claudio Foschi, and Maria Carla Re
March 2023, BMC microbiology,
Antonella Marangoni, and Chiara Zalambani, and Giacomo Marziali, and Melissa Salvo, and Romana Fato, and Claudio Foschi, and Maria Carla Re
February 1978, Infection and immunity,
Copied contents to your clipboard!